Monday, October 2, 2023
Projects In Knowledge® adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests)*. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
*An ineligible company (commercial interest) is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used, on patients.
Off-Label Drug Statement: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This activity is supported by an independent educational grant from Daiichi Sankyo and AstraZeneca.
Professor of Medicine
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Professor of Medicine and Oncology
Lombardi Comprehensive Cancer Center, Georgetown University
Washington, DC
Kirstin Bass (medical writer) has no relevant financial relationships.
Peer Reviewer has no relevant financial relationships.
Vandana G. Abramson, MD (IPE Committee) has no relevant financial relationships.
Jason D. Astrin, DMSc, MBA, PA-C, DFAAPA (IPE Committee) has no relevant financial relationships.
James D. Bowen, MD (IPE Committee), has received honoraria from Biogen, EMD Serono, Inc., Genentech, and Novartis; has received consulting fees from Biogen, Celgene, EMD Serono, Genentech, a Member of the Roche Group, and Novartis Pharmaceuticals Corporation; has conducted contracted research for Alexion Pharmaceuticals, Inc, Alkermes, Biogen, Celgene Corporation, Genentech, a Member of the Roche Group, Genzyme, Novartis Pharmaceuticals Corporation, and TG Therapeutics, Inc; and has ownership interest in Amgen Inc.
Anita Roy Desai, MD, FAAP (IPE Committee), has no relevant financial relationships.
Veronica Esquible, PharmD (IPE Committee), has no relevant financial relationships.
Bradley J. Monk, MD, FACOG, FACS (IPE Committee), has received consulting fees from AbbVie, Inc.; Advaxis, Inc.; Agenus, Inc.; Amgen, Inc.; Aravive, Inc.; Asymmetric Therapeutics; Boston Biomedical; Chemocare; ChemoID; Circulogene; Conjupro Biotherapeutics, Inc.; Eisai Co., Ltd.; Geistlich Pharma North America, Inc.; Genmab/Seattle Genetics; GOG Foundation; Immunomedics, Inc.; ImmunoGen, Inc.; Incyte Corporation; Laekna Healthcare Private Limited; Mateon Therapeutics; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Mersana Therapeutics, Inc.; Myriad Genetics; Nucana; OncoMed Pharmaceuticals; OncoQuest, Inc.; OncoSec Medical, Inc.; Perthera, Inc.; Pfizer, Inc.; Precision Oncology; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals; Samumed, LLC; Takeda Pharmaceutical Company, Ltd.; VBL Therapeutics; Vigeo Therapeutics; and has been a Speaker/Consultant for AstraZeneca; Clovis Oncology; F. Hoffmann-La Roche Ltd/ Genentech; A Member of the Roche Group; Janssen Pharmaceuticals/Johnson & Johnson, Inc.; and Tesaro, Inc./GlaxoSmithKline.
Brant Oliver, PhD, MS, MPH, APRN-BC (IPE Committee), has conducted contracted research for Biogen and EMD Serono.
Ilon S. Rincon Portas, MD (IPE Committee), has no relevant financial relationships to disclose.
Kendall Shultes, PharmD, BCOP (IPE Committee), has no relevant financial relationships to disclose.
Katherine Sibler, MSN, WHNP-BC (IPE Committee), has no relevant financial relationships to disclose.
Projects In Knowledge staff members have no relevant financial relationships to disclose.
Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™
Nurses - 1.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)
Physician Assistant - 1.50 AAPA hour(s) of Category I credit
IPCE - 1.50 Interprofessional Continuing Education (IPCE) credit
The target audience for this activity includes the team that manages and cares for patients with gastric cancer, specifically: oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other relevant healthcare professionals.
The goal of this program is to provide the most current clinical information and practical management strategies on the complex challenges in gastric cancer management as seen in clinical practice, and provide complementary education interventions in an interactive and easily digestible on-demand video.
Upon completion of this activity, participants will be able to:
Projects In Knowledge® adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests)*. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
*An ineligible company (commercial interest) is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used, on patients.
Off-Label Drug Statement: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This activity is supported by an independent educational grant from Daiichi Sankyo and AstraZeneca.
Professor of Medicine
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Professor of Medicine and Oncology
Lombardi Comprehensive Cancer Center, Georgetown University
Washington, DC
Kirstin Bass (medical writer) has no relevant financial relationships.
Peer Reviewer has no relevant financial relationships.
Vandana G. Abramson, MD (IPE Committee) has no relevant financial relationships.
Jason D. Astrin, DMSc, MBA, PA-C, DFAAPA (IPE Committee) has no relevant financial relationships.
James D. Bowen, MD (IPE Committee), has received honoraria from Biogen, EMD Serono, Inc., Genentech, and Novartis; has received consulting fees from Biogen, Celgene, EMD Serono, Genentech, a Member of the Roche Group, and Novartis Pharmaceuticals Corporation; has conducted contracted research for Alexion Pharmaceuticals, Inc, Alkermes, Biogen, Celgene Corporation, Genentech, a Member of the Roche Group, Genzyme, Novartis Pharmaceuticals Corporation, and TG Therapeutics, Inc; and has ownership interest in Amgen Inc.
Anita Roy Desai, MD, FAAP (IPE Committee), has no relevant financial relationships.
Veronica Esquible, PharmD (IPE Committee), has no relevant financial relationships.
Bradley J. Monk, MD, FACOG, FACS (IPE Committee), has received consulting fees from AbbVie, Inc.; Advaxis, Inc.; Agenus, Inc.; Amgen, Inc.; Aravive, Inc.; Asymmetric Therapeutics; Boston Biomedical; Chemocare; ChemoID; Circulogene; Conjupro Biotherapeutics, Inc.; Eisai Co., Ltd.; Geistlich Pharma North America, Inc.; Genmab/Seattle Genetics; GOG Foundation; Immunomedics, Inc.; ImmunoGen, Inc.; Incyte Corporation; Laekna Healthcare Private Limited; Mateon Therapeutics; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Mersana Therapeutics, Inc.; Myriad Genetics; Nucana; OncoMed Pharmaceuticals; OncoQuest, Inc.; OncoSec Medical, Inc.; Perthera, Inc.; Pfizer, Inc.; Precision Oncology; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals; Samumed, LLC; Takeda Pharmaceutical Company, Ltd.; VBL Therapeutics; Vigeo Therapeutics; and has been a Speaker/Consultant for AstraZeneca; Clovis Oncology; F. Hoffmann-La Roche Ltd/ Genentech; A Member of the Roche Group; Janssen Pharmaceuticals/Johnson & Johnson, Inc.; and Tesaro, Inc./GlaxoSmithKline.
Brant Oliver, PhD, MS, MPH, APRN-BC (IPE Committee), has conducted contracted research for Biogen and EMD Serono.
Ilon S. Rincon Portas, MD (IPE Committee), has no relevant financial relationships to disclose.
Kendall Shultes, PharmD, BCOP (IPE Committee), has no relevant financial relationships to disclose.
Katherine Sibler, MSN, WHNP-BC (IPE Committee), has no relevant financial relationships to disclose.
Projects In Knowledge staff members have no relevant financial relationships to disclose.
Provided by Projects in Knowledge
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Interprofessional Education (IPE) requires collaboration among and between professions in order to enhance skills and strategies for effective healthcare team practices including communication and coordination of care. In guiding the overall CE Program, the role of the IPE Committee is to improve interprofessional collaborative practice by helping to recognize the different roles, responsibilities, and expertise of other healthcare professionals to develop team strategies that improve outcomes.
The IPE Committee members include:
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Sr. Director, Advanced Practice Provider Services
The US Oncology Network
Keller, Texas
Medical Director, Multiple Sclerosis Center
Swedish Neuroscience Institute
Seattle, Washington
Executive Director of Patient Simulation
i-Human Patients by Kaplan
Kaplan North America
Fort Lauderdale, Florida
Clinical Lead Pharmacist
Department of Pharmacotherapy
Swedish Medical Center
Seattle, Washington
Arizona Oncology (US Oncology Network)
Professor, Gynecologic Oncology
University of Arizona and Creighton University
Medical Director of US Oncology Research Gynecology Program
Phoenix, Arizona
Healthcare Improvement Scientist
Associate Professor
The Dartmouth Institute & Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
Executive Director
Kaplan Medical Prep
Kaplan North America
Fort Lauderdale, Florida
Clinical Pharmacy Specialist
Stem Cell Transplant & Cellular Therapies
VA Tennessee Valley Healthcare System
Nashville, Tennessee
Nurse Practitioner
Vanderbilt Breast Center
Nashville, Tennessee
Upon completion of this course, participants will be awarded 1.50 nursing contact hour(s).
Joint Accreditation Nursing Provider Number: 4008235
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, or PIK endorsement of any commercial product or service.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This chapter is worth up to 1.50 contact hour(s)(0.05 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is JA4008235-0000-23-188-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
Projects In Knowledge® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 Credit(s)™. Approval is valid until 6/24/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 100% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / CE Released: 6/30/2023
Valid for credit through: 6/30/2024, 11:59 PM EST
processing....
This CME activity is based on the slides and lectures presented by the faculty for the program, “Advancing the HER2+ Treatment Paradigm in Gastric/GEJ Cancers”. It was developed by Projects In Knowledge for distribution on Medscape.org.
To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
Please answer these questions to complement your learning experience.
